← FDA DRUG APPROVALS

FDA ANDA · ANDA207092

CASPOFUNGIN ACETATE

Sponsor: GLAND

APPLICATION
ANDA207092
TYPE
ANDA
ORIGINAL APPROVAL
2017-09-29
LATEST ACTION
2019-09-05
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription

Products

CASPOFUNGIN ACETATEPrescription
CASPOFUNGIN ACETATE 70MG/VIAL · POWDER · INTRAVENOUS
CASPOFUNGIN ACETATEPrescription
CASPOFUNGIN ACETATE 50MG/VIAL · POWDER · INTRAVENOUS

Approval history

2019-09-05Labeling · Supplement 3 · standardAP
2019-09-05Labeling · Supplement 1 · standardAP
2017-09-29UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →